New strategy could prevent T cell exhaustion and boost immunotherapy
Researchers at Memorial Sloan Kettering Cancer Center have identified that the signaling molecule MEK contributes to T cell exhaustion in cancer patients. Blocking MEK could potentially extend the effectiveness of immunotherapy treatments.
Why it matters
This discovery offers a promising pathway to improve the long-term success rates of cancer immunotherapies, which often fail when immune cells become fatigued.
by Jim Stallard, Memorial Sloan Kettering Cancer Center
edited by Lisa Lock , reviewed by Robert Egan
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: Immunity (2026). DOI: 10.1016/j.immuni.2026.06.012 A major pillar of cancer immunotherapy involves stimulating T cells, the specialized killers of the immune system, to attack tumors. But this strategy has been undermined by the tendency of T cells to tire out before finishing the job. When the cells reach a fatigued stage—called T cell exhaustion—they lose the ability to sustain the attack and keep cancer growth under control.
This has been a significant problem for checkpoint inhibitor drugs, a type of immunotherapy that releases a brake on T cells to spur them into action.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in